News
NCNA
0.2600
-15.21%
-0.0467
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Kodiak Sciences shares dipped 19.9% to $5.97 on Thursday. The company reported a wider-than-expected fourth-quarter loss. Avalo Therapeutics, Inc. Shares jumped 430% in today's mid-day session. Other stocks moving in the market include RH, Ggoorks and Xilio.
Benzinga · 20h ago
12 Health Care Stocks Moving In Thursday's Intraday Session
Avalo Therapeutics (NASDAQ:AVTX) stock rose 363.1% to $22.0 during Thursday's regular session. The company's market cap stands at $17.6 million. Biodexa Pharmaceuticals and Ontrak stock increased by 71.82% and 37.66% respectively. Q4 earnings came out today.
Benzinga · 21h ago
Why NuCana (NCNA) Shares Are Trading Lower
NuCana plc shares are trading lower by 15.2% to $0.26. Company says it intends to adjust ratio of its American Depository Shares to its ordinary shares from 1:1 to 1:25. The change is expected to be effective around April 16.
Benzinga · 22h ago
BUZZ-U.S. STOCKS ON THE MOVE-Gold miners, B Riley, Xilio Therapeutics
Wall Street's main stock indexes set to open flat on Thursday in thin trading ahead of Easter break. Dow e-minis up 0.11%, S&P 500 and Nasdaq 100 down 0.02%. Top three NYSE percentage gainers premarket: Cazoo Group, Xilio Therapeutics. Gold miners rise on U.S. Interest rate cut bets. B Riley Financial up 6.7% in premarket.
Reuters · 1d ago
Why RH Shares Are Trading Higher By Around 9%; Here Are 20 Stocks Moving Premarket
RH posted weaker-than-expected results for its fourth quarter, but issued upbeat forecast. The company's shares jumped 9.4% to $324.99 in pre-market trading. Avalo Therapeutics, Inc. Gained 256.6% on Wednesday.
Benzinga · 1d ago
Truist Financial Sticks to Its Buy Rating for Nucana (NCNA)
Robyn Karnauskas from Truist Financial maintained a Buy rating on Nucana. The company’s shares closed yesterday at $0.31. The firm has a one-year high of $1.00 and a low of $.23. The analyst consensus rating suggests a Moderate Buy.
TipRanks · 1d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Avalo Therapeutics (NASDAQ:AVTX) shares rose 328.2% to $20.34 during Thursday's pre-market session. Xilio Therapeutic (XLO) stock moved upwards by 223.94% during the session. Akanda (AKAN) shares increased by 27.1% and INVO Bioscience (INVO) stock increased by 16.36%. NuCana (NCNA) stock declined by 19.8% in the pre- market.
Benzinga · 1d ago
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
Pre-market stock movers are a hot topic on Thursday. Avalo Therapeutics stock is rocketing more than 268% after announcing a $185 million private placement. Moving stocks this morning are public debuts, earnings reports and more. Ten of the biggest pre-market stocks moving shares this morning.
Investorplace · 1d ago
NuCana plc Announces Reverse ADS Split
TipRanks · 1d ago
NuCana announces plan to implement ADS ratio change
Healthcare NuCana announces plan to implement ADS ratio change. Shares of NCNA fell 5.4% in extended trading. The change in the ADS Ratio is expected to become effective on or about April 16. NCNA plans to change the ratio of its American Depository Shares to its ordinary shares.
Seeking Alpha · 1d ago
Weekly Report: what happened at NCNA last week (0318-0322)?
Weekly Report · 4d ago
Nucana (NCNA) Receives a Hold from TD Cowen
TD Cowen analyst Tara Bancroft maintained a Hold rating on Nucana (NCNA – Research Report) yesterday. The company’s shares closed last Friday at $0.30. The analyst covers the Healthcare sector and has a 63.16% success rate on recommended stocks.
TipRanks · 4d ago
NCNA Stock Earnings: NuCana Misses EPS for Q4 2023
NuCana reported earnings per share of -17 cents for the fourth quarter of 2023. The company did not report any revenue for the quarter. This was below the analyst estimate for EPS of -13 cents. NuCana also reported results for the third quarter of 2018.
Investorplace · 03/21 01:53
NuCana GAAP EPS of -£0.14
As of December 31, 2023, NuCana had cash and cash equivalents of £17.2 million. The company had a Q4 GAAP EPS of -£0.14. In 2024, the company is expected to announce data from a colorectal cancer study.
Seeking Alpha · 03/20 21:00
NuCana Plc Shows Positive Advances in Cancer Treatments
TipRanks · 03/20 20:57
12 Health Care Stocks Moving In Monday's After-Market Session
Ontrak (NASDAQ:OTRK) stock increased by 61.0% to $0.31 during Monday's after-market session. Universe Pharmaceuticals (NASdaq:UPC) shares rose 30.26% in the same session. Augmedix and Sophia Genetics also moved upwards. Losers Acurx Pharmaceuticals, Acutus Medical and Fresh2 Group were among the names in the losers.
Benzinga · 03/18 21:33
Nucana Filed U.S. Patent Application #20240082287: Formulations Of Phosphoramidate Derivatives Of Nucleoside Drugs
Benzinga · 03/14 19:53
12 Health Care Stocks Moving In Wednesday's After-Market Session
Molina Healthcare (NYSE:MOH) stock moved upwards by 24.2% to $503.11 during Wednesday's after-market session. The company's market cap stands at $29.3 billion. Evoke Pharma (NASDAQ:EVOK) shares rose 18.54% and Aptorum Gr stock rose 11.75% during the session. Losers Spruce Biosciences and Bright Green stock declined by 75.2%.
Benzinga · 03/13 21:32
Dow Surges Over 100 Points; Dollar Tree Earnings Miss Expectations
Dollar Tree, Inc. Reported worse-than-expected fourth-quarter financial results. Energy shares jumped by 1.7% on Wednesday. The Dow Jones gained over 100 points on Wednesday and the NASDAQ fell 0.25%. U.S. Stocks traded mixed toward the end of trading.
Benzinga · 03/13 18:32
12 Health Care Stocks Moving In Wednesday's Intraday Session
Heron Therapeutics shares rose 35.4% to $3.19 during Wednesday's regular session. The company's, Q4 earnings came out yesterday. Trxade Health (NASDAQ:MEDS) shares fell 22.6% during the session. NuCana stock rose 34.32% and Cardiff Oncology shares increased by 27.9%.
Benzinga · 03/13 17:31
More
Webull provides a variety of real-time NCNA stock news. You can receive the latest news about Nucana through multiple platforms. This information may help you make smarter investment decisions.
About NCNA
NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-3373, and NUC-7738. NUC-3373 is a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil (5-FU). 5-FU is a prescribed anti-cancer agent. NUC-3373 has been evaluated in a Phase I clinical trial for patients with advanced solid tumors and is under Phase Ib/II clinical trial for patients with advanced colorectal cancer. NUC-7738 is a ProTide transformation of a nucleoside analog, 3’-deoxyadenosine (3’-Da). The Company is evaluating NUC-7738 in a Phase I/II clinical trial for patients with advanced solid tumors. Its pipeline also includes Acelari. The Company’s subsidiaries include NuCana, Inc., NuCana Limited and NuCana BioMed Trustee Company Limited.